Evoke Pharma, Inc. is a specialty pharmaceutical company focused on the development and commercialization of drugs to treat gastrointestinal disorders and diseases. It develops, commercializes and markets GIMOTI, a nasal spray formulation of metoclopramide, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in adults. Gimoti is a dopamine antagonist / mixed 5-HT3 antagonist / 5-HT4 agonist with pro-motility and anti-emetic effects, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis. Gimoti offers systemic delivery by nasal spray administration. It has developed a nasal formulation of metoclopramide to provide its targeted patient population with recurrent symptoms of diabetic gastroparesis with a product that is systemically delivered as an alternative to the oral or intravenous routes of administration. The nasal formulation delivers metoclopramide to patients with delayed gastric emptying and/or frequent vomiting.
企業コードEVOK
会社名Evoke Pharma Inc
上場日Sep 25, 2013
最高経営責任者「CEO」D'Onofrio (Matthew J)
従業員数3
証券種類Ordinary Share
決算期末Sep 25
本社所在地420 Stevens Avenue
都市SOLANA BEACH
証券取引所NASDAQ OMX - NASDAQ BASIC
国United States of America
郵便番号92075
電話番号18583451494
ウェブサイトhttps://evokepharma.com/
企業コードEVOK
上場日Sep 25, 2013
最高経営責任者「CEO」D'Onofrio (Matthew J)
過去5年間の配当金総支払額は
0.00
米ドルである。

データなし